Bruker Corporation - BRKR STOCK NEWS

Bruker Corporation (Nasdaq: BRKR) has launched the timsTOF MALDI PharmaPulse®, a groundbreaking high-throughput screening system at the SLAS2022 International Conference. This innovative platform combines Trapped Ion Mobility Spectrometry and high-resolution mass spectrometry for unmatched assay specificity. With speeds of 10 kHz, it supports various HTS applications, promising to enhance drug discovery by reducing false discovery rates. The software integration allows seamless data transfer for efficient analysis and demonstrates significant advancements in drug molecule design.

Bruker Corporation (NASDAQ: BRKR) announced its acquisition of Danish company PepSep, enhancing its nanoLC offerings. This acquisition aims to optimize nanoflow proteomics workflows, particularly for Bruker’s nanoElute® UHPLC system. Additionally, Bruker established an OEM agreement with IonOpticks to produce high-performance nanoLC Aurora columns. Both PepSep and IonOpticks solutions are designed to improve the performance and ease of use of the timsTOF 4D-Proteomics solutions, which is essential for high-throughput proteomics applications.

Bruker Corporation (Nasdaq: BRKR) will report its fourth quarter and fiscal year 2021 financial results on February 11, 2022, before market opening. A conference call and webcast will follow at 8:30 a.m. EST. Investors can access the call via Bruker’s investor relations website, and a telephone replay will be available until March 11, 2022. The company specializes in high-performance scientific instruments, enabling research across various life science and industrial applications.

Bruker Corporation (Nasdaq: BRKR) has acquired Prolab Instruments GmbH, a Swiss firm specializing in high-precision low-flow liquid chromatography technology. This acquisition is expected to enhance Bruker’s capabilities in proteomics and metabolomics, integrating Prolab's unique Zirconium™ products, including the Zirconium Qube autosampler and Zirconium Ultra UHPLC systems. Prolab's innovations will improve high-performance mass spectrometry workflows, particularly for single-cell proteomics, validating Bruker's strategy in expanding its analytical solutions portfolio.

Bruker Corporation (Nasdaq: BRKR) will participate in the 40^th annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The Company’s Chairman and CEO, Frank Laukien, along with Executive Vice President and CFO, Gerald Herman, will present on January 10 at 9:00 AM EST. A live audio webcast of this presentation will be accessible on the Investor Relations section of Bruker's website, with a replay available for 30 days post-event. Bruker focuses on high-performance scientific instruments, enhancing life sciences research and diagnostics.

Bruker has launched the JPK NanoWizard® V BioAFM, advancing atomic force microscopy for life sciences. This automated system integrates seamlessly with optical microscopes, facilitating rapid mechanobiological measurements from sub-molecular to cellular scales. Key features include enhanced speed, resolution, and user-friendly automation, promoting long-term experiments. Experts believe this innovation could greatly enhance the understanding of cellular processes. Bruker aims to leverage its decade-long experience in quantitative nanomechanics to empower researchers in the biomedical field.

Bruker Corporation (Nasdaq: BRKR) has completed a private placement of 10-year senior notes totaling $500 million to enhance financial flexibility and support growth initiatives. The issuance includes 300 million Swiss Franc 0.88% Series A senior notes and 150 million Euro 1.03% Series B senior notes, both due December 8, 2031. The funds will be used for general corporate purposes, including repaying maturing debts. The financing capitalizes on favorable interest rates, locking in fixed costs for the next decade.

Bruker Corporation (Nasdaq: BRKR) announced its CE-IVD marked FluoroType^® SARS-CoV-2 varID Q PCR assay, capable of detecting all major variants of SARS-CoV-2, including Omicron (B.1.1.529). The assay identifies key S-gene mutations associated with Omicron and provides viral load results in less than 4 hours. It is validated for use with the FluoroCycler^® XT thermocycler and supports automated extraction via the GenoXtract^® fleXT system. Bruker’s other SARS-CoV-2 assays are also expected to detect the Omicron variant.

Bruker Corporation (Nasdaq: BRKR) announced its acquisition of MOLECUBES NV, enhancing its nuclear molecular imaging (NMI) capabilities. This strategic move aims to expand Bruker's preclinical imaging portfolio with the modular benchtop CUBES™ systems, expected to accelerate NMI adoption in medical and biopharma sectors. MOLECUBES generated approximately Euro 5 million in FY 2020 revenue and will operate within Bruker's BioSpin division, aiming for synergies in research and development.